Inspire’s Diquafosol Is “Approvable” For Dry Eye; FDA Requests Efficacy Data
Executive Summary
Inspire Pharmaceuticals hopes that supplemental Phase III data on the dry eye agent diquafosol (INS 365) will help address efficacy questions raised by FDA in a Dec. 19 "approvable" letter